Alumis

SAN FRANCISCO, Sept. 1, 2026 Alumis Inc. announced topline results from its Phase 2b LUMUS trial of envudeucitinib in...

SOUTH SAN FRANCISCO, California, August 10, 2026 Alumis Inc. announced topline long-term results from the ongoing Phase 3 ONWARD3...